Vandetanib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB05294 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | renal cell carcinoma (disease) | KG + DL |
| 2 | renal cell carcinoma associated with neuroblastoma | KG + DL |
| 3 | renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions | KG + DL |
| 4 | unclassified renal cell carcinoma | KG + DL |
| 5 | renal pelvis carcinoma | KG + DL |
| 6 | clear cell renal carcinoma | KG + DL |
| 7 | childhood kidney cell carcinoma | KG + DL |
| 8 | renal carcinoma | KG + DL |
| 9 | angiolipoma | KG + DL |
| 10 | familial spontaneous pneumothorax | KG + DL |
| 11 | endocrine-cerebro-osteodysplasia syndrome | KG + DL |
| 12 | nonpapillary renal cell carcinoma | KG + DL |
| 13 | sarcomatoid renal cell carcinoma | KG + DL |
| 14 | chromophobe renal cell carcinoma | KG + DL |
| 15 | collecting duct carcinoma | KG + DL |
| 16 | liposarcoma | KG + DL |
| 17 | ovarian myxoid liposarcoma | KG + DL |
| 18 | kidney medullary carcinoma | KG + DL |
| 19 | acquired cystic disease-associated renal cell carcinoma | KG + DL |
| 20 | cystic renal cell carcinoma | KG + DL |
| 21 | glycogen storage disease due to lactate dehydrogenase H-subunit deficiency | KG + DL |
| 22 | multilocular clear cell renal cell carcinoma | KG + DL |
| 23 | paroxysmal dyskinesia | KG + DL |
| 24 | renal pelvis adenocarcinoma | KG + DL |
| 25 | undifferentiated carcinoma of liver and intrahepatic biliary tract | KG + DL |
| 26 | spindle cell liposarcoma | KG + DL |
| 27 | gallbladder papillary neoplasm with an associated invasive carcinoma | KG + DL |
| 28 | Wolffian duct adenocarcinoma | KG + DL |
| 29 | amyotrophic lateral sclerosis | KG + DL |
| 30 | renal cell adenocarcinoma | KG + DL |
| 31 | papillary lung adenocarcinoma | KG + DL |
| 32 | X-linked hydrocephalus with stenosis of the aqueduct of Sylvius | KG + DL |
| 33 | papillary thymic adenocarcinoma | KG + DL |
| 34 | X-linked complicated corpus callosum dysgenesis | KG + DL |
| 35 | Mills syndrome | KG + DL |
| 36 | pyruvate dehydrogenase E1-beta deficiency | KG + DL |
| 37 | amyotrohpic lateral sclerosis type 22 | KG + DL |
| 38 | bilateral parasagittal parieto-occipital polymicrogyria | KG + DL |
| 39 | adenocarcinoma of liver and intrahepatic biliary tract | KG + DL |
| 40 | amyotrophic lateral sclerosis, susceptibility to | KG + DL |
| 41 | papillary cystadenocarcinoma | KG + DL |
| 42 | 3M syndrome | KG + DL |
| 43 | thyroid lymphoma | KG + DL |
| 44 | classic variant of chromophobe renal cell carcinoma | KG + DL |
| 45 | axial spondylometaphyseal dysplasia | KG + DL |
| 46 | childhood malignant neoplasm | KG + DL |
| 47 | papillary renal cell carcinoma | KG + DL |
| 48 | extrahepatic bile duct adenocarcinoma | KG + DL |
| 49 | childhood malignant kidney neoplasm | KG + DL |
| 50 | monomelic amyotrophy | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.